RxDoctor Payments Data

Glen Elliott

Optometrist · Hanover, PANPI 1851383830

Payments from drug & device makers

$2,010in general payments, 2019–2025

Across 97 payments — averaging $20.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sun Pharmaceutical Industries Inc.$683
  • AbbVie$356
  • Tarsus Pharmaceuticals, Inc.$208
  • Bausch & Lomb Americas Inc.$201
  • Oyster Point Pharma, Inc.$165
  • Dompe US, Inc.$133
  • plus $264 from 8 others

What the payments were for

  • Food & beverage$2,010100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,010 in reported general payments places this provider in the 75th percentile of 2,165 optometrist providers in Pennsylvania.

See all optometrist providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$239,756
Medicare patients
1,188
Services billed
3,601

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine229$291,901
XiidraLifitegrast80$128,189
Cyclosporine185$122,394
LumiganBimatoprost73$43,011
CequaCyclosporine35$32,071
MieboPerfluorohexyloctane/Pf32$27,938
TyrvayaVarenicline Tartrate26$19,271
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol49$12,019
VyzultaLatanoprostene Bunod13$5,874
SimbrinzaBrinzolamide/Brimonidine Tart17$4,926
Brinzolamide16$4,675
CombiganBrimonidine Tartrate/Timolol12$4,535
Doxycycline Hyclate34$3,840
Brimonidine Tartrate48$3,723
Travoprost20$2,756

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$356$339,447314 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta$201$162,001125 claims
Sun Pharmaceutical Industries Inc.Cequa$683$32,07135 claims
Oyster Point Pharma, Inc.Tyrvaya$165$19,27126 claims
AlconSimbrinza$80$4,92617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,165 optometrist providers in Pennsylvania.

Other optometrist in Hanover

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →